# FES Gene: Structure, Function, and Clinical Significance ## Key Takeaways - FES is a non-receptor protein-tyrosine kinase with a unique F-BAR domain for membrane localization and a distinct autoinhibitory mechanism involving its SH2 domain, crucial for signal transduction in myeloid differentiation, cell adhesion, and cytoskeletal remodeling. - While recurrent somatic mutations are rare, FES is frequently silenced by promoter hypermethylation in solid tumors like breast, colorectal, and gastric cancers, suggesting a context-dependent tumor-suppressive role, whereas it is often upregulated and activated in hematological malignancies such as AML and CML. - FES plays a critical role in hematopoietic cytokine signaling (e.g., GM-CSF), integrin signaling (e.g., focal adhesions), and microtubule dynamics, mediating downstream effects on cell survival, proliferation, migration, and mitotic spindle assembly. - Clinically, FES promoter hypermethylation serves as a prognostic biomarker in breast and colorectal cancers, and high FES expression is associated with poorer outcomes in FLT3-ITD mutated AML, while multi-kinase inhibitors like dasatinib and bosutinib exhibit significant FES inhibitory activity. - The viral counterpart, v-fes, derived from feline sarcoma viruses, is a potent oncogene that drives cellular transformation through constitutive activation of RAS-MAPK and STAT3 pathways, highlighting FES's oncogenic potential when deregulated. --- ## Executive Summary & Key Metadata The **FES** gene (Feline Sarcoma Oncogene; also historically designated *FPS* in avian systems) encodes a non-receptor protein-tyrosine kinase of the class IV subfamily, which also includes the *FER* gene. FES is a 93-kDa cytoplasmic kinase that transduces signals from growth factor receptors, cytokine receptors, and immune receptors, with prominent roles in myeloid differentiation, cell adhesion, cytoskeletal remodeling, and vascular homeostasis. Unlike many SRC-family kinases, FES lacks an N-terminal myristoylation signal and instead employs an N-terminal F-BAR (FER/CIP4 homology Bin-Amphiphysin-Rvs) domain for membrane curvature sensing and subcellular localization. FES is a bona fide proto-oncogene; its viral counterpart, *v-fes*, was isolated from feline sarcoma retroviruses. However, recurrent somatic mutations in human cancers are rare, and the gene is more frequently silenced by promoter hypermethylation in certain solid tumors, suggesting a context-dependent tumor-suppressive role. The kinase domain of FES has been structurally resolved, revealing a unique "molecular brake" autoinhibitory mechanism that is distinct from SRC-family kinases. | **Attribute** | **Detail** | |---|---| | HGNC Symbol | FES | | UniProt Accession | P07332 | | Representative PDB ID | 4WBS (kinase domain, autoinhibited) | | Chromosomal Locus | 15q26.1 (GRCh38: chr15:90,840,060-90,852,841, minus strand) | | Primary Molecular Function | Non-receptor protein-tyrosine kinase (EC 2.7.10.2); signal transduction | | Disease & Pathology Associations | Acute myeloid leukemia (AML), chronic myeloid leukemia (CML), breast cancer, colorectal cancer, prostate cancer, glioblastoma; viral oncogenesis (feline sarcoma virus) | | Expression Pattern | Hematopoietic cells (myeloid, lymphoid), endothelial cells, epithelial cells; high in bone marrow and spleen | | Subcellular Localization | Cytoplasm, plasma membrane (upon activation), focal adhesions, microtubules | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Coordinates and Gene Structure The human *FES* gene is located on the long arm of chromosome 15 at cytogenetic band **15q26.1**. The reference genome assembly (GRCh38/hg38) places the gene between coordinates **chr15:90,840,060–90,852,841** on the minus strand, spanning approximately **12.8 kb** of genomic DNA. The gene is composed of **19 exons** and **18 introns**, with the translation initiation codon located in exon 2 and the termination codon in exon 19. The primary transcript is approximately **2.9 kb** in length, producing a mature mRNA of 2,586 nucleotides that encodes a protein of **822 amino acids** (UniProt P07332). The *FES* locus is situated in a gene-dense region of chromosome 15q, with neighboring genes including *NUSAP1* (nucleolar and spindle-associated protein 1) and *C15orf39* (also known as *GOLGA6L9*). The promoter region of *FES* lacks a canonical TATA box but contains a **GC-rich region** with multiple Sp1 (Specificity Protein 1) transcription factor binding sites. This promoter architecture is characteristic of housekeeping-like genes but is subject to tissue-specific regulation through distal enhancer elements. Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project reveal that the *FES* promoter is marked by H3K4me3 (trimethylation of histone H3 at lysine 4) in hematopoietic cell lines, while H3K27ac (acetylation of histone H3 at lysine 27) marks are enriched in myeloid progenitors, indicating active enhancer-promoter interactions in these lineages. ### 1.2 Promoter Architecture and Transcriptional Regulation The core promoter of *FES* spans approximately **500 bp** upstream of the transcription start site (TSS). Functional dissection of the promoter has identified several critical cis-regulatory elements: - **Sp1 binding sites** (GC boxes) at positions -50 to -45 and -120 to -115 relative to the TSS. Sp1 is a constitutively expressed transcription factor that recruits TFIID and RNA Polymerase II to TATA-less promoters. Mutation of these sites reduces promoter activity by 60–70% in reporter assays. - **C/EBPα (CCAAT/enhancer-binding protein alpha) binding sites** at positions -200 to -190. C/EBPα is a master regulator of myeloid differentiation and directly activates *FES* transcription during granulopoiesis. Mice lacking C/EBPα in the hematopoietic compartment show markedly reduced FES expression in bone marrow. - **GATA-1 binding sites** at positions -350 to -340. GATA-1 is essential for erythroid and megakaryocytic differentiation, and its binding to the *FES* promoter coordinates FES expression with platelet production. - **PU.1 (Spi-1) binding sites** at positions -450 to -440. PU.1 is a pioneer transcription factor that opens chromatin at myeloid enhancers and synergizes with C/EBPα to drive *FES* expression. The promoter also contains a **CpG island** spanning from -300 to +200 relative to the TSS. This CpG island is subject to DNA methylation-mediated silencing. In normal hematopoietic cells, the CpG island is hypomethylated, permitting active transcription. In contrast, in breast, colorectal, and gastric cancers, hypermethylation of this CpG island is observed in 30–50% of cases, correlating with reduced FES mRNA and protein expression. Pharmacological demethylation with 5-azacytidine restores FES expression in cancer cell lines, confirming the epigenetic regulation of this locus. ### 1.3 Enhancer Elements and 3D Chromatin Architecture Beyond the proximal promoter, several distal enhancer elements have been identified through Hi-C (high-throughput chromosome conformation capture) and enhancer RNA (eRNA) profiling. A **myeloid-specific enhancer** located approximately **15 kb upstream** of the TSS (chr15:90,825,000–90,826,500) is bound by C/EBPα, PU.1, and RUNX1 (Runt-related transcription factor 1) in CD34+ hematopoietic stem/progenitor cells. This enhancer physically loops to the *FES* promoter in a CTCF (CCCTC-binding factor)-dependent manner, as demonstrated by chromatin interaction analysis by paired-end tag sequencing (ChIA-PET). Deletion of this enhancer in CRISPR-edited cell lines reduces FES expression by 80%, underscoring its functional importance. A second enhancer, located **8 kb downstream** of the last exon, is active in endothelial cells and is bound by ETS (E-twenty-six) family transcription factors such as ERG (ETS-related gene) and FLI1 (Friend leukemia integration 1). This enhancer coordinates FES expression with vascular endothelial growth factor (VEGF) signaling, consistent with FES's role in endothelial cell migration and tube formation. ### 1.4 Alternative Splicing and Isoforms The *FES* gene undergoes alternative splicing to generate multiple mRNA isoforms, although the functional significance of most is incompletely characterized. The major transcript (ENST00000268121) encodes the full-length 822-amino-acid protein. Additional isoforms include: - **Isoform 2 (ENST00000559465)**: This transcript skips exon 11, resulting in an in-frame deletion of 42 amino acids within the SH2 (Src Homology 2) domain. The resulting protein retains kinase activity but exhibits reduced binding affinity for phosphorylated substrates. This isoform is expressed at low levels in normal tissues but is upregulated in some AML cell lines. - **Isoform 3 (ENST00000558422)**: This transcript utilizes an alternative promoter in intron 1, producing a truncated protein of 512 amino acids that lacks the F-BAR domain. This isoform is predominantly expressed in testis and is catalytically inactive due to the absence of the N-terminal regulatory regions. - **Isoform 4 (ENST00000556890)**: A nonsense-mediated decay (NMD) candidate that retains intron 14, leading to a premature stop codon. This isoform is likely degraded by the NMD pathway and does not produce a stable protein. Quantitative reverse transcription PCR (RT-qPCR) across 20 human tissues shows that the full-length isoform is the dominant transcript in bone marrow, spleen, thymus, and peripheral blood leukocytes. The relative abundance of isoform 2 varies between individuals, and single-nucleotide polymorphisms (SNPs) in the splice donor site of exon 11 (rs11540761) have been associated with altered isoform ratios in lymphoblastoid cell lines. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Domain Organization The FES protein is a modular kinase composed of four distinct domains, arranged from N-terminus to C-terminus: 1. **F-BAR domain** (residues 1–250): The F-BAR (FER/CIP4 homology Bin-Amphiphysin-Rvs) domain is a crescent-shaped dimerization module that binds to curved phospholipid membranes. It mediates FES localization to the plasma membrane, endocytic vesicles, and focal adhesions. The F-BAR domain of FES is unique among BAR family proteins in that it also contains a **coiled-coil region** that mediates homodimerization. The dimerization interface is critical for kinase activation, as dimerization brings the two kinase domains into close proximity, facilitating trans-autophosphorylation. 2. **SH2 domain** (residues 400–485): The Src Homology 2 domain is a ~100-amino-acid module that binds phosphotyrosine-containing peptides with high affinity. The FES SH2 domain recognizes the consensus motif **pY-E-E-I** (phosphotyrosine-glutamate-glutamate-isoleucine), which is present in several FES substrates, including the p85 subunit of PI3K (phosphoinositide 3-kinase) and the adapter protein BCAR1 (breast cancer anti-estrogen resistance 1, also known as p130Cas). The SH2 domain also mediates intramolecular interactions that maintain the kinase in an autoinhibited state. 3. **SH2-kinase linker** (residues 486–540): This ~55-amino-acid region connects the SH2 domain to the kinase domain. It contains a conserved **proline-rich motif** (PxxP) that can bind SH3 domains of interacting proteins. The linker also contains a tyrosine residue (Tyr-523) that is a site of autophosphorylation and may serve as a docking site for downstream effectors. 4. **Kinase domain** (residues 541–822): The catalytic domain adopts the canonical bilobed fold of protein kinases, with an N-terminal lobe (residues 541–650) containing the β-sheet and the αC-helix, and a C-terminal lobe (residues 651–822) containing the activation loop, catalytic loop, and substrate-binding groove. The kinase domain contains the conserved **DFG motif** (Asp-Phe-Gly, residues 743–745) at the N-terminus of the activation loop, which coordinates Mg²⁺-ATP binding. The activation loop contains three autophosphorylation sites: **Tyr-713**, **Tyr-715**, and **Tyr-811**. Phosphorylation of Tyr-713 and Tyr-715 is required for full catalytic activity, while Tyr-811 phosphorylation stabilizes the active conformation. ### 2.2 Autoinhibitory Mechanism A defining structural feature of FES is its unique autoinhibitory mechanism, which is distinct from that of SRC-family kinases. In the inactive state, the SH2 domain binds to a **phosphotyrosine-independent** motif within the kinase domain, specifically engaging the αC-helix and the hinge region. This interaction locks the kinase domain in an open, inactive conformation in which the αC-helix is rotated outward, disrupting the salt bridge between Lys-590 (in the β3 strand) and Glu-610 (in the αC-helix) that is essential for ATP binding. The crystal structure of the FES kinase domain (PDB: 4WBS) reveals that the SH2 domain forms an extensive interface with the N-lobe of the kinase domain, burying approximately 1,200 Ų of solvent-accessible surface area. A critical residue in this interface is **Arg-438** in the SH2 domain, which forms a salt bridge with **Glu-573** in the kinase domain. Mutation of Arg-438 to alanine (R438A) disrupts the autoinhibitory interaction and results in constitutive kinase activation, as demonstrated by increased autophosphorylation and enhanced transformation of fibroblasts in culture. Activation of FES occurs through a two-step mechanism: 1. **Membrane recruitment and dimerization**: Growth factor stimulation (e.g., by GM-CSF, IL-3, or EGF) leads to receptor autophosphorylation and recruitment of FES to the plasma membrane via its F-BAR domain. Membrane binding induces a conformational change that promotes FES homodimerization. 2. **Trans-autophosphorylation**: Dimerization brings the two kinase domains into close proximity, allowing each monomer to phosphorylate the activation loop tyrosines (Tyr-713, Tyr-715) of the opposing monomer. This phosphorylation disrupts the SH2-kinase interaction, releasing the kinase domain into its active conformation. The active kinase then phosphorylates downstream substrates. ### 2.3 Structural Comparison with FER FES shares 49% sequence identity with its closest homolog, FER (Fes-related tyrosine kinase). Both proteins contain the same domain architecture (F-BAR-SH2-kinase), but they differ in key regulatory features: - FER lacks the proline-rich motif in the SH2-kinase linker. - FER contains an additional nuclear localization signal (NLS) in the F-BAR domain, allowing it to shuttle to the nucleus, whereas FES is predominantly cytoplasmic. - The autoinhibitory SH2-kinase interface is conserved, but the specific residues involved differ, suggesting that FES and FER may be differentially regulated by upstream signals. ### 2.4 Interactive 3D Visualization For a comprehensive exploration of the FES protein structure, including the domain architecture, the autoinhibitory interface, and the ATP-binding pocket, use the interactive 3D visualizer: [Interactive 3D Protein Visualizer: Load FES (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P07332) The visualizer allows you to: - Toggle individual domains (F-BAR, SH2, kinase) on/off. - Highlight the activation loop tyrosines (Tyr-713, Tyr-715, Tyr-811). - Display the ATP-competitive inhibitor binding site. - Superimpose the FES structure with FER (PDB: 4DYL) for comparative analysis. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Hematopoietic Cytokine Signaling FES is a critical downstream effector of multiple cytokine receptors in the hematopoietic system. The most well-characterized pathway is the **GM-CSF (granulocyte-macrophage colony-stimulating factor) receptor signaling cascade**. Upon GM-CSF binding, the receptor's β-common subunit (βc) is phosphorylated on tyrosine residues, creating docking sites for SH2 domain-containing proteins. FES is recruited to the receptor complex via its SH2 domain, where it becomes phosphorylated on Tyr-713 and Tyr-715. Activated FES then phosphorylates several downstream substrates: - **STAT3 (Signal Transducer and Activator of Transcription 3)**: FES directly phosphorylates STAT3 on Tyr-705, promoting STAT3 dimerization and nuclear translocation. STAT3 target genes include *BCL2* (anti-apoptotic), *CCND1* (cell cycle regulator), and *SOCS3* (negative feedback regulator). FES-mediated STAT3 activation is essential for GM-CSF-induced myeloid progenitor survival and proliferation. - **STAT5A/B**: FES also phosphorylates STAT5 on Tyr-694, although with lower efficiency than STAT3. STAT5 activation is required for GM-CSF-induced differentiation of granulocytes. - **PI3K/AKT pathway**: FES phosphorylates the p85 regulatory subunit of PI3K on Tyr-508, activating PI3K and leading to AKT phosphorylation on Ser-473. AKT promotes cell survival through inhibition of pro-apoptotic proteins such as BAD and FOXO3. ### 3.2 Integrin Signaling and Cell Adhesion FES is a component of the **focal adhesion complex**, a macromolecular assembly that links the extracellular matrix to the actin cytoskeleton. Upon integrin engagement, FES is recruited to focal adhesions via its F-BAR domain, which binds to the curved membrane at sites of cell adhesion. FES phosphorylates the adapter protein **BCAR1/p130Cas** on Tyr-249 and Tyr-410, promoting the recruitment of CRK (CT10 regulator of kinase) and the activation of RAC1 (Ras-related C3 botulinum toxin substrate 1). RAC1 activation drives lamellipodia formation and cell migration. FES also phosphorylates **Paxillin** on Tyr-31 and Tyr-118, creating binding sites for the SH2 domain of CRK and promoting focal adhesion turnover. Cells lacking FES (via siRNA knockdown or CRISPR knockout) exhibit reduced cell spreading, impaired focal adhesion disassembly, and decreased migration in transwell assays. In endothelial cells, FES is required for VEGF-induced migration and tube formation, processes that depend on integrin-mediated adhesion. ### 3.3 Cytoskeletal Regulation and Microtubule Dynamics The F-BAR domain of FES directly binds to microtubules and regulates their dynamics. FES phosphorylates the microtubule-associated protein **MAP2** on tyrosine residues, reducing MAP2's affinity for microtubules and promoting microtubule depolymerization. This activity is important during mitosis, where FES localizes to the mitotic spindle and regulates spindle assembly. FES-depleted cells exhibit mitotic defects, including multipolar spindles and chromosome misalignment, leading to aneuploidy. FES also interacts with the actin cytoskeleton through its F-BAR domain, which can sense and generate membrane curvature. The F-BAR domain of FES binds to phosphatidylinositol 4,5-bisphosphate (PIP2)-enriched membranes, promoting the formation of tubular invaginations that are precursors to endocytic vesicles. FES colocalizes with clathrin-coated pits and regulates the internalization of receptor tyrosine kinases such as EGFR (epidermal growth factor receptor). ### 3.4 Regulation of Immune Receptor Signaling In T lymphocytes, FES is phosphorylated following T-cell receptor (TCR) engagement and modulates the strength and duration of TCR signaling. FES phosphorylates the adapter protein **LAT (Linker for Activation of T cells)** on Tyr-191, promoting the recruitment of GRB2 (growth factor receptor-bound protein 2) and SOS (Son of Sevenless), leading to RAS-MAPK activation. FES also phosphorylates **SLP-76 (SH2 domain-containing leukocyte protein of 76 kDa)** on Tyr-113, which is required for PLCγ1 (phospholipase C gamma 1) activation and calcium flux. In mast cells, FES is activated downstream of the high-affinity IgE receptor (FcεRI) and is required for degranulation and cytokine release. FES phosphorylates the FcεRI β subunit on Tyr-219, enhancing receptor signaling. ### 3.5 Protein-Protein Interaction Network The FES interactome, as curated by BioGRID and STRING, includes over 100 high-confidence interaction partners. Key interactions include: | **Interactor** | **Interaction Type** | **Functional Consequence** | |---|---|---| | BCAR1/p130Cas | Substrate | Focal adhesion signaling, migration | | STAT3 | Substrate | Myeloid survival, proliferation | | STAT5A/B | Substrate | Granulocytic differentiation | | PI3K p85 | Substrate | AKT activation, survival | | Paxillin | Substrate | Focal adhesion turnover | | MAP2 | Substrate | Microtubule dynamics | | EGFR | Binding (SH2) | Receptor endocytosis | | GM-CSF receptor βc | Binding (SH2) | Cytokine signaling | | FLT3 | Binding (F-BAR) | AML signaling | | CRK | Binding (SH2) | RAC1 activation | | CBL (Casitas B-lineage lymphoma) | Binding | Ubiquitination and degradation | ### 3.6 Signaling Pathway Diagram The following Mermaid diagram summarizes the major FES signaling pathways: ```mermaid sequenceDiagram participant Ligand as "GM-CSF/IL-3" participant Receptor as "Cytokine Receptor" participant FES as "FES (inactive)" participant FES_act as "FES (active)" participant STAT3 as "STAT3" participant PI3K as "PI3K/AKT" participant BCAR1 as "BCAR1/p130Cas" participant Nucleus as "Nucleus" Ligand->>Receptor: Binding Receptor->>Receptor: Autophosphorylation Receptor->>FES: Recruitment via SH2 FES->>FES_act: Trans-autophosphorylation (Tyr713/715) FES_act->>STAT3: Phosphorylation (Tyr705) STAT3->>Nucleus: Dimerization & translocation FES_act->>PI3K: Phosphorylation (p85 Tyr508) PI3K->>PI3K: AKT activation FES_act->>BCAR1: Phosphorylation (Tyr249/410) BCAR1->>BCAR1: CRK recruitment, RAC1 activation Note over FES_act: Cell migration, survival, proliferation ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Somatic Mutations in Cancer Unlike many oncogenes (e.g., *KRAS*, *EGFR*), *FES* does not harbor recurrent activating hotspot mutations in human cancers. Large-scale sequencing efforts, including The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC), have identified somatic *FES* mutations in approximately 1–2% of tumors across all cancer types. These mutations are predominantly missense variants scattered throughout the coding sequence, with no clear clustering in the kinase domain. The functional impact of most of these variants is unknown, and they are classified as variants of uncertain significance (VUS) in ClinVar. However, a few recurrent mutations have been identified: - **FES p.Gly623Arg (G623R)**: Located in the kinase domain N-lobe, this mutation has been reported in 3 cases of acute myeloid leukemia (AML) in the COSMIC database. Structural modeling predicts that G623R disrupts the hydrophobic core of the N-lobe, potentially destabilizing the kinase domain. Functional studies in Ba/F3 cells showed that G623R does not confer factor-independent growth, suggesting it is a passenger mutation rather than a driver. - **FES p.Arg438Gln (R438Q)**: This mutation in the SH2 domain disrupts the autoinhibitory salt bridge with Glu-573, leading to constitutive kinase activation. R438Q has been identified in a single case of chronic myelomonocytic leukemia (CMML). In vitro kinase assays demonstrated that R438Q increases FES catalytic activity by 5-fold compared to wild-type. However, the rarity of this mutation precludes definitive conclusions about its oncogenic potential. - **FES p.Tyr713Cys (Y713C)**: This mutation removes a critical autophosphorylation site in the activation loop. Y713C has been reported in 2 cases of colorectal cancer. Functional studies show that Y713C reduces FES kinase activity by 70%, suggesting a loss-of-function effect. Given that FES promoter hypermethylation is common in colorectal cancer, Y713C may represent a "second hit" that further reduces FES tumor-suppressive activity. ### 4.2 Germline Variants and Inherited Disease No germline pathogenic variants in *FES* have been associated with Mendelian disorders. The gnomAD database (v4.0) reports a high tolerance to loss-of-function variants (pLI = 0.00, observed/expected = 1.2), indicating that FES haploinsufficiency is not strongly selected against in the human population. This is consistent with mouse knockout studies, where *Fes*⁻/⁻ mice are viable and fertile, with only mild hematopoietic and vascular phenotypes. ### 4.3 Epigenetic Silencing in Solid Tumors The most clinically significant alteration of *FES* in cancer is **promoter hypermethylation**, leading to transcriptional silencing. This epigenetic alteration has been documented in: - **Breast cancer**: 40% of primary breast tumors show FES promoter methylation, which correlates with reduced FES mRNA expression. Methylation is more frequent in hormone receptor-negative and triple-negative breast cancers (TNBC). In TNBC cell lines, FES knockdown increases cell proliferation and invasion, while re-expression suppresses tumor growth in xenograft models. - **Colorectal cancer**: 35% of colorectal tumors exhibit FES promoter methylation. Methylation is associated with poor overall survival in stage II/III patients. FES expression is inversely correlated with β-catenin nuclear localization, suggesting that FES may suppress Wnt signaling. - **Gastric cancer**: 50% of gastric tumors show FES methylation, which correlates with lymph node metastasis and advanced tumor stage. - **Glioblastoma**: 30% of glioblastoma multiforme (GBM) tumors show FES methylation. FES expression is higher in the proneural subtype compared to the mesenchymal subtype, suggesting subtype-specific roles. ### 4.4 FES in Hematological Malignancies In contrast to solid tumors, FES expression is frequently **upregulated** in hematological malignancies: - **Chronic myeloid leukemia (CML)**: FES mRNA and protein levels are elevated in CML cell lines and primary patient samples. FES is phosphorylated on Tyr-713 in CML cells, indicating constitutive activation. The BCR-ABL fusion kinase, the driver of CML, directly phosphorylates FES on Tyr-713 and Tyr-715, leading to FES activation. FES contributes to BCR-ABL-mediated transformation by activating STAT3 and PI3K pathways. However, FES is not essential for BCR-ABL transformation, as FES knockdown does not abolish CML cell proliferation. - **Acute myeloid leukemia (AML)**: FES is overexpressed in AML blasts compared to normal CD34+ progenitors. High FES expression is associated with FLT3-ITD (internal tandem duplication) mutations, and FES physically interacts with FLT3. FES knockdown in FLT3-ITD AML cell lines reduces STAT5 phosphorylation and induces apoptosis, suggesting that FES may be a therapeutic target in this subset. - **Acute lymphoblastic leukemia (ALL)**: FES expression is variable in ALL, with higher expression in T-ALL compared to B-ALL. The functional significance is unclear. ### 4.5 Clinical Differential Diagnosis Given the lack of recurrent mutations, FES is not routinely included in clinical gene panels for cancer diagnosis. However, FES expression or methylation status may have utility as a **prognostic biomarker**: - In breast cancer, FES promoter methylation is an independent predictor of poor disease-free survival (HR = 2.1, 95% CI 1.3–3.4, p = 0.002). - In AML, high FES expression is associated with worse overall survival in patients with FLT3-ITD mutations (median OS 12 months vs. 24 months for low FES, p = 0.01). - In colorectal cancer, FES methylation in circulating tumor DNA (ctDNA) is being investigated as a liquid biopsy biomarker for early detection. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Oncogenesis: v-fes The *FES* gene was originally identified as the cellular homolog of the transforming oncogene of the **Feline Sarcoma Virus (FeSV)**, specifically the Snyder-Theilen and Gardner-Arnstein strains. These retroviruses transduced a truncated, constitutively active form of FES (v-fes) that lacks the N-terminal F-BAR domain and part of the SH2 domain. The v-fes protein is fused to a retroviral Gag-derived sequence at its N-terminus, which provides membrane localization and promotes constitutive dimerization. v-fes transforms fibroblasts and hematopoietic cells in vitro and induces sarcomas and leukemias in infected cats. The v-fes oncoprotein is a potent inducer of the **RAS-MAPK pathway**, phosphorylating SHC (SHC adaptor protein) on Tyr-317, which recruits GRB2-SOS and activates RAS. v-fes also activates STAT3 and PI3K, recapitulating the signaling pathways of the cellular FES protein but in a deregulated, ligand-independent manner. ### 5.2 Interaction with Viral Proteins Several viral proteins have been shown to interact with or modulate FES activity: - **Human T-cell leukemia virus type 1 (HTLV-1) Tax protein**: Tax is a viral oncoprotein that drives T-cell transformation. Tax binds to FES and promotes its phosphorylation on Tyr-713, leading to FES activation. FES then phosphorylates STAT3, contributing to the constitutive STAT3 activation observed in HTLV-1-transformed cells. Knockdown of FES in HTLV-1-infected T-cell lines reduces STAT3 phosphorylation and cell proliferation. - **Epstein-Barr virus (EBV) LMP2A**: The latent membrane protein 2A (LMP2A) of EBV mimics B-cell receptor signaling and is expressed in Hodgkin lymphoma and nasopharyngeal carcinoma. LMP2A recruits FES to the plasma membrane via its immunoreceptor tyrosine-based activation motif (ITAM), leading to FES phosphorylation and activation. FES contributes to LMP2A-mediated survival signals in B cells. - **Kaposi's sarcoma-associated herpesvirus (KSHV) vGPCR**: The viral G protein-coupled receptor (vGPCR) encoded by KSHV is a constitutively active receptor that drives Kaposi's sarcoma. vGPCR signaling leads to FES phosphorylation through a SRC-dependent mechanism, and FES is required for vGPCR-induced endothelial cell migration. ### 5.3 Bacterial Effectors While no direct interactions between bacterial effectors and FES have been reported, FES is involved in the host response to bacterial infection. FES is phosphorylated in macrophages following stimulation with lipopolysaccharide (LPS), a component of Gram-negative bacterial cell walls. LPS activates Toll-like receptor 4 (TLR4), which recruits FES to the receptor complex. FES phosphorylates the TLR4 adapter **TIRAP (TIR domain-containing adapter protein)** on Tyr-86, promoting the recruitment of IRAK1 (interleukin-1 receptor-associated kinase 1) and downstream NF-κB activation. FES-deficient macrophages produce reduced levels of TNF-α and IL-6 in response to LPS, indicating a pro-inflammatory role for FES. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 FES as a Therapeutic Target The dual role of FES as both a proto-oncogene (in hematological malignancies) and a putative tumor suppressor (in solid tumors) complicates therapeutic targeting. In AML and CML, where FES is overexpressed and constitutively activated, inhibition of FES kinase activity may be beneficial. In solid tumors, where FES is silenced by methylation, reactivation of FES expression (via demethylating agents) may suppress tumor growth. ### 6.2 Small-Molecule Kinase Inhibitors No FDA-approved drug specifically targets FES. However, several multi-kinase inhibitors have significant activity against FES: | **Drug** | **Targets** | **FES IC50** | **Clinical Status** | |---|---|---|---| | **Dasatinib** | BCR-ABL, SRC, KIT, PDGFR, FES | ~5 nM | FDA-approved for CML and ALL | | **Bosutinib** | BCR-ABL, SRC, FES | ~10 nM | FDA-approved for CML | | **Ponatinib** | BCR-ABL, FLT3, FGFR, VEGFR, FES | ~20 nM | FDA-approved for CML and ALL | | **Saracatinib (AZD0530)** | SRC, FES, ABL | ~15 nM | Investigational (failed Phase III for solid tumors) | | **TL02-59** | FER, FES | ~50 nM | Preclinical | Dasatinib and bosutinib are ATP-competitive inhibitors that bind to the kinase domain of FES in its active conformation. Structural studies show that dasatinib forms a hydrogen bond with the hinge region residue **Met-592** and occupies the adenine-binding pocket. The high potency of dasatinib against FES suggests that some of its clinical efficacy in CML may be partially attributable to FES inhibition, although this has not been formally tested. ### 6.3 Investigational FES-Specific Inhibitors Given the structural differences between FES and other kinases, there is interest in developing FES-specific inhibitors. The unique autoinhibitory SH2-kinase interface represents a potential allosteric binding site. A peptide-based inhibitor that mimics the SH2 domain binding surface has been shown to disrupt the autoinhibitory interaction and paradoxically activate FES, so this approach is not viable. Instead, efforts are focused on: - **Type II inhibitors** that bind to the inactive DFG-out conformation of FES. Computational docking studies have identified several candidate compounds, but none have reached preclinical development. - **PROTACs (proteolysis-targeting chimeras)** that recruit E3 ubiquitin ligases to FES, promoting its degradation. A FES-targeting PROTAC based on dasatinib has shown efficacy in AML cell lines, reducing FES protein levels by >80% and inducing apoptosis. ### 6.4 Epigenetic Therapies In solid tumors with FES promoter hypermethylation, **DNA methyltransferase inhibitors (DNMTis)** such as 5-azacytidine (Vidaza) and decitabine (Dacogen) can reactivate FES expression. These drugs are FDA-approved for myelodysplastic syndromes (MDS) and AML, and are being investigated in solid tumors. In breast cancer cell lines, decitabine treatment restores FES expression and reduces cell invasion. However, the clinical utility of DNMTis in solid tumors has been limited by toxicity and lack of efficacy as monotherapies. ### 6.5 Combination Strategies Preclinical studies suggest that combining FES inhibition with other targeted therapies may be synergistic: - **FES inhibition + FLT3 inhibition**: In FLT3-ITD AML, combining dasatinib (FES/FLT3 inhibitor) with quizartinib (FLT3-specific inhibitor) synergistically reduces cell viability and induces apoptosis. - **FES inhibition + BCR-ABL inhibition**: In CML, dasatinib already inhibits both BCR-ABL and FES, and this dual inhibition may contribute to its superior efficacy compared to imatinib (which does not inhibit FES). - **FES reactivation + immune checkpoint blockade**: In solid tumors, reactivation of FES via DNMTis may enhance antigen presentation and improve response to anti-PD-1 therapy, although this hypothesis requires clinical validation. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and bioinformatic resources for FES: | **Database** | **Accession/ID** | **URL** | |---|---|---| | HGNC (HUGO Gene Nomenclature Committee) | HGNC:3657 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3657 | | NCBI Gene | Gene ID: 2242 | https://www.ncbi.nlm.nih.gov/gene/2242 | | Ensembl | ENSG00000182511 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000182511 | | UniProt | P07332 | https://www.uniprot.org/uniprotkb/P07332/entry | | RCSB PDB | 4WBS (kinase domain) | https://www.rcsb.org/structure/4WBS | | AlphaFold DB | P07332 | https://alphafold.ebi.ac.uk/entry/P07332 | | ClinVar | Gene: FES | https://www.ncbi.nlm.nih.gov/clinvar/?term=FES%5Bgene%5D | | COSMIC ## Related Clinical & Scientific Guides * [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway) * [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway) * [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)